Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial

被引：0
|
作者：
Liu, Zengjun
Liu, Mengyao
Xu, Jing
Hu, Wenyu
Zhu, Dongyuan
Tao, Rongjie
Xu, Ni
Zhang, Hui
Li, Minghuan
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
[4] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[5] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol & Radiol, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11553
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma
    Yao, Weitao
    Du, Xinhui
    Wang, Jiaqiang
    Wang, Xin
    Zhang, Peng
    Niu, Xiaohui
    ONCOTARGETS AND THERAPY, 2022, 15 : 669 - 679
  • [32] Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single-arm, multicenter, phase II clinical trial-Update results from ALTER-C001
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTERGO-010)
    Cheng, Wenjun
    Jiang, Yi
    Gao, Yingchun
    Chen, Youguo
    Cai, Yunlang
    Zhou, Huaijun
    Xue, Jinling
    Yu, Jinjin
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S77 - S78
  • [34] The efficacy and safety of sequential use of anlotinib and 131I for locally advanced or metastatic differentiated thyroid cancer: A single-arm phase II clinical trial
    Song, Hongjun
    Qiu, Xian
    He, Ziyan
    Chen, Libo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study
    Liu, Jie
    Deng, Yaotiao
    Wang, Ying
    Zhang, Jie
    Li, Mei
    Jiang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
    Chen, Xiaofeng
    Li, Wei
    Wu, Xiaofeng
    Zhao, Fengjiao
    Wang, Deqiang
    Wu, Hao
    Gu, Yanhong
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Li, Changxian
    Xia, Yongxiang
    Rao, Jianhua
    Dai, Xinzheng
    Shao, Qianwen
    Tang, Jie
    Li, Xiangcheng
    Shu, Yongqian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Durvalumab and pazopanib in patients with advanced soft tissue sarcoma: A single-center, single-arm, phase 2 trial.
    Kim, Hyo Song
    Cho, Hee Jin
    Yun, Kum-Hee
    Lee, Young Han
    Kim, Sung Hyun
    Baek, Wooyeol
    Jeon, Min Kyung
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
    Tian, Zhichao
    Liu, Huimin
    Zhang, Fan
    Li, Liangyu
    Du, Xinhui
    Li, Chao
    Yan, Jinpo
    Wang, Jiaqiang
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1559 - 1569
  • [39] Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
    Zhichao Tian
    Huimin Liu
    Fan Zhang
    Liangyu Li
    Xinhui Du
    Chao Li
    Jinpo Yang
    Jiaqiang Wang
    Investigational New Drugs, 2020, 38 : 1559 - 1569
12345